Abrdn Life Sciences InvestorsHQL.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Abrdn Life Sciences Investors (HQL.N) trades at a P/E of N/A, P/B of 0.91x, P/S of N/A, and a dividend yield of 10.36%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 30th percentile over the trailing 10Y window (vs. 30th percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 80th percentile within its industry and the 26th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 10.36%, ranking at the 85th percentile over the trailing 20Y window.
The P/B percentile sits lower across the market than within its own industry — relatively cheaper next to the market as a whole. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Abrdn Life Sciences Investors operates in the other sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: HQL · HQL
Want the full picture on whether Abrdn Life Sciences Investors (HQL.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | N/A | — | — | — | — | — | — |
| P/B (MRQ) | 0.91 | ||||||
| P/S (TTM) | N/A | — | — | — | — | — | — |
| Dividend Yield | 10.36% | ||||||
| Buyback + Div Yield | 10.36% |